Mesenchymal Stem Cell Industry â MSC Products, Technologies and Deal-Making in Marketplace
The Mesenchymal Stem Cells – Advances & Applications report explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 35 leading competitors within the MSC marketplace.
November 23, 2015 /MarketersMedia/ —
The Mesenchymal Stem Cells – Advances & Applications report says 2015 saw the first “thaw and use” ink to make MSCs readily available for 3D printing (RoosterBio and CELLINK), a novel manufacturing approach to produce a nearly unlimited supply of MSCs from iPSCs derived from a single donor (Cynata Therapeutics), and the recommendation for approval of a MSC product in Japan (JR-031 developed by Mesoblast’s Japanese partner, JCR Pharmaceuticals Co. Ltd). It is clear that the scope of the MSC industry is expanding and advanced analytics are required.
The complete report on Mesenchymal Stem Cells – Advances & Applications spreads across 250 pages, analysis 35 market leaders and provides data tables & figures is available at http://www.reportsnreports.com/reports/10598-mesenchymal-stem-cells-advances-applications.html.
In addition, the report describes the current status of MSC research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and possible uses of MSCs in cell therapy. Because MSCs are a sub-segment of the broader cell therapy (CT) and regenerative medicine (RM) markets, it also gives an overview of the regenerative medicine industry and overall cell therapy industry.
The report also explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 35 leading competitors within the MSC marketplace. For pharmaceutical companies, it reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.
Opportunities for Commercializing Mesenchymal Stem Cells:
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, other cell types. MSCs are of intense therapeutic interest, because they represent a population of cells with the potential to treat a range of acute and degenerative diseases. They are advantageous over other stem cells types for a variety of reasons. They avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs also being explored for use in 3D printing applications, because of their unique capacity to form structural tissues. Order a Copy of Mesenchymal Stem Cells – Advances & Applications Report at http://www.reportsnreports.com/purchase.aspx?name=10598.
Because MSCs represent a valuable market segment, stem cell executives and investors must to have a clear understanding of opportunities and threats occurring within the marketplace. As the technology surrounding MSC production has advanced, novel approaches to MSC manufacturing have emerged. As clinical trials investigating MSCs have increased in number, new companies have entered the marketplace to explore clinical applications.
Other emerging threats that could impact the MSC industry include inconsistent or negative clinical findings, competing technologies, and the potential for other stem cell types to provide better efficiency or function. Fluctuating government perspectives on whether the manipulation of stem cells prior to transplantation into humans should be allowed is also a current “hot topic” among regulatory bodies within the U.S. and other regions worldwide, with such legislation affecting the Regenexx® technology and other therapeutic applications involving MSCs.
However, there is also great potential for growth of the MSC market, with more than 30,000 scientific publications published about the cell type, more than 400 clinical trials underway worldwide, and Google Trend data showing MSC searches to be more than twice as common as the next most popular stem cell type.
Therefore, the main objectives of the report are to consider the following:
• Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular
• Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells
• Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types
• The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their ongoing search for MSCs-based cell therapy products
• Analysis of traditional market metrics (grant rates, clinical trial rates, patent rates, scientific publication rates) and new social analytics (metrics from social media sites, search engines, Google Trends, and more)
Company Profiles: American Type Culture Collection Inc. (ATCC), Anterogen Co., Ltd., Apceth GmbH & Co. KG, BioCardia Inc., BioRestorative Therapies Inc., Bone Therapeutics SA, BrainStorm Cell Therapeutics Inc., CellGenix Technologie Transfer GmbH, Celprogen Inc., CellTherapies P/L and more.
Explore other reports on Stem Cells by BioInformant at http://www.reportsnreports.com/publisher/bioinformant-worldwide-llc/.
About US:
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. Call +1 888 391 5441 with industry research requirements or email, the details on sales at reportsandreports.com.
For more information about us, please visit http://www.reportsnreports.com/reports/10598-mesenchymal-stem-cells-advances-applications.html
Contact Info:
Name: Ritesh Tiwari
Email: sales@reportsandreports.com
Organization: ReportsnReports.com
Phone: + 1 888 391 5441
Release ID: 97313
Copyright © 1999-2013 SproutNews.com
